Coherus BioSciences, Inc. (CHRS)
| Market Cap | 115.03M |
| Revenue (ttm) | 266.96M |
| Net Income (ttm) | 28.51M |
| Shares Out | 115.92M |
| EPS (ttm) | 0.25 |
| PE Ratio | 3.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 871,777 |
| Open | 0.9507 |
| Previous Close | 0.9462 |
| Day's Range | 0.9489 - 1.0000 |
| 52-Week Range | 0.6600 - 2.4300 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 5.26 (+430.08%) |
| Earnings Date | May 12, 2025 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 m... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $5.26, which is an increase of 430.08% from the latest price.
News
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market c...
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming confere...
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion...
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep...
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlight...
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok...
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over...
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be releas...
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at t...
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS hol...
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 mi...
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare C...
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA ® net revenue, quarter-over-quarter –
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market ...
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Coherus BioSciences, Inc. focuses on biosimilars and immuno-oncology treatments, with LOQTORZI and UDENYCA as key products. Coherus BioSciences' biosimilar IP shows potential for profitability, with s...
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief E...
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market...
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli. CHS-114, an anti-CCR8 antibody being develop...
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Con...
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncolog...